OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics Ltd. (“PsiOxus”), the immuno-oncology company, has appointed Dr Paolo Paoletti, MD as Chairman of the Board.
Dr Paoletti was most recently the President of GlaxoSmithKline (GSK) Oncology, a global role in which he championed the fight against the causes and impacts of cancer. In this role, he was responsible for R&D, commercial strategy, and lifecycle management, and shared the accountability of GSK Oncology’s P&L with its regional commercial leaders. Prior to joining GSK, Dr Paoletti was Vice President, Clinical Development for Lilly Oncology.
